{"id":683919,"date":"2025-08-08T05:00:38","date_gmt":"2025-08-08T02:00:38","guid":{"rendered":"https:\/\/buradabiliyorum.com\/en\/stem-cell-startup-proclaims-inflection-point-for-medicine-as-mass-production-nears\/"},"modified":"2025-08-08T05:00:38","modified_gmt":"2025-08-08T02:00:38","slug":"stem-cell-startup-proclaims-inflection-point-for-medicine-as-mass-production-nears","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/stem-cell-startup-proclaims-inflection-point-for-medicine-as-mass-production-nears\/","title":{"rendered":"Stem cell startup proclaims \u2018inflection point\u2019 for medicine as mass production nears"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a3fa8ab47c56\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #dd3333;color:#dd3333\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #dd3333;color:#dd3333\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a3fa8ab47c56\" checked aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/buradabiliyorum.com\/en\/stem-cell-startup-proclaims-inflection-point-for-medicine-as-mass-production-nears\/#The_power_of_MSCs\" >The power of MSCs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/buradabiliyorum.com\/en\/stem-cell-startup-proclaims-inflection-point-for-medicine-as-mass-production-nears\/#A_new_world_of_treatments\" >A new world of treatments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/buradabiliyorum.com\/en\/stem-cell-startup-proclaims-inflection-point-for-medicine-as-mass-production-nears\/#The_new_antibiotics\" >The new antibiotics?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/buradabiliyorum.com\/en\/stem-cell-startup-proclaims-inflection-point-for-medicine-as-mass-production-nears\/#Scaling_for_the_future\" >Scaling for the future<\/a><\/li><\/ul><\/nav><\/div>\n<div id=\"article-main-content\">\n<p><span style=\"font-weight: 400;\">It\u2019s harvest day at the Karolinska Institute in Stockholm. As sunshine bathes the leafy university campus, scientists inside the labs work under cool fluorescent light. Clad in green protective gear, they tend meticulously to test tubes within hermetically sealed cleanrooms. The containers hold the fruits of today\u2019s labour: mesenchymal stem cells (MSCs).<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Each cell is barely a quarter the width of a human hair but wields remarkable power. MSCs reduce inflammation, repair damaged tissue, and modulate the immune system. They can treat chronic diseases and delay ageing. They may even prevent illness before it begins. But to become a mainstay of modern healthcare, MSCs must be produced at scale, affordably and reliably.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">That seemed a distant prospect until recently, but the Karolinska scientists believe it\u2019s <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/download-scripts-themes-apps\/\" data-internallinksmanager029f6b8e52c=\"9\" title=\"Download Scripts &amp; Themes &amp; Apps\" target=\"_blank\" rel=\"noopener\">app<\/a>roaching reality. They\u2019re working for <a rel=\"nofollow\" target=\"_blank\" href=\"https:\/\/cellcolabs.com\/\" target=\"_blank\" rel=\"nofollow noopener\">Cellcolabs<\/a>, a Swedish startup\u00a0formed to tackle the global scarcity of stem cell treatments.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Cellcolabs believes this shortage could soon be overcome. Thanks to a blend of scientific, regulatory, and technological advances, MSCs are edging towards the consumer market. Within the next decade, Cellcolabs aims to cut prices by up to 90%.<\/span><\/p>\n<div class=\"inarticle-wrapper latest channel-cta hs-embed-tnw\">\n<div id=\"hs-embed-tnw\" class=\"channel-cta-wrapper\">\n<div class=\"channel-cta-img\"><img decoding=\"async\" class=\"js-lazy\" src=\"https:\/\/s3.eu-west-1.amazonaws.com\/tnw.events\/hardfork-2018\/uploads\/visuals\/tnw-newsletter.png\"\/><\/div>\n<p><img decoding=\"async\" src=\"https:\/\/s3.eu-west-1.amazonaws.com\/tnw.events\/hardfork-2018\/uploads\/visuals\/tnw-newsletter.png\"\/><\/p>\n<div class=\"channel-cta-input\">\n<p class=\"channel-cta-title\">The \ud83d\udc9c of EU tech<\/p>\n<p class=\"channel-cta-tagline\">The latest rumblings from the EU tech scene, a story from our wise ol&#8217; founder Boris, and some questionable AI art. It&#8217;s free, every week, in your inbox. Sign up now!<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p>In the lab, the progress looks impressive. The latest harvest \u2014 cultivated from a single donation \u2014 has yielded 4.1 billion cells, enough for up to 200 standard doses.<\/p>\n<p><span style=\"font-weight: 400;\">Cellcolabs CEO Dr Mattias Bernow is in a buoyant mood. The 43-year-old sees today\u2019s harvest as just a taste of what\u2019s to come.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cI truly believe that we\u2019re at an inflection point in the history of medicine,\u201d he says.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"The_power_of_MSCs\"><\/span>The power of MSCs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">MSCs exist naturally in the body. A typical human contains billions of them. They act like a repair crew, fixing and tuning our insides. They can also be extracted, multiplied, and turned into medical treatments.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Karolinska was the site of one of the field\u2019s biggest milestones. In 2012, its Nobel Assembly awarded the Nobel Prize in Physiology or Medicine to <a rel=\"nofollow\" target=\"_blank\" href=\"https:\/\/www.bbc.com\/news\/health-19869673\" target=\"_blank\" rel=\"nofollow noopener\">John Gurdon and Shinya Yamanaka<\/a>. They discovered that mature cells can be made pluripotent \u2014 able to become almost any cell type in the body. The breakthrough rewrote the rules of regenerative medicine, igniting fresh regulatory momentum and fast-tracking stem cell therapies.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">MSCs are among the most promising examples. When injected, they release signals that trigger healing. The body then repairs itself.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">They can treat countless conditions, from arthritis and heart disease to immune disorders. But first, you need to extract a small sample from a living, breathing human.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Cellcolabs sources its MSCs from the bone marrow of healthy donors aged 18 to 30. Just 50 millilitres \u2014 about a shot glass \u2014 produces up to 200 doses. The marrow naturally regenerates in six to eight weeks.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The donation process is quick and minimally invasive, but mass production is notoriously challenging. MSCs are living cells that require complex biomanufacturing, careful handling, and strict quality control, which makes scaling a formidable task.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Cellcolabs nonetheless sees industrial-scale production on the horizon \u2014 largely thanks to the pioneering research of Professor Katarina Le Blanc.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Le Blanc\u2019s landmark work showed MSCs could combat inflammatory and immune diseases. Her findings also proved that donated cells were suitable for therapeutic use \u2014 a crucial step for commercialisation.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">She helped establish clinical-grade production standards, paving the way for large-scale trials and broader therapeutic use. Her research laid the foundations for Bernow\u2019s inflection point.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cThis is not brain surgery or rocket <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/sciencee\/\" data-internallinksmanager029f6b8e52c=\"5\" title=\"Science\" target=\"_blank\" rel=\"noopener\">science<\/a>, but it is stem cells \u2014 so it\u2019s quite close,\u201d he says. \u201cIt\u2019s super complex. And the only reason we can do this and move so fast is Professor Le Blanc\u2019s research.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">As a haematologist, Le Blanc explored the potential of MSCs to support blood cancer patients. Her early clinical work focused on graft-versus-host disease \u2014 a severe and often fatal complication of bone marrow transplants. In a small trial, her team administered MSCs to patients who hadn\u2019t responded to standard therapies. The impact was striking: more than half the participants survived. \u201cThe entire field just blew up,\u201d says Bernow.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Le Blanc continued pushing into new territory. One trial repaired vocal folds, restoring speech with minimal scarring. Another study used MSCs in COVID-19 patients to reduce inflammation. The results were promising \u2014 but she hit a wall. \u201cShe ran out of cells,\u201d Bernow says.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Scaling became a new focus. To expand treatment access, Le Blanc co-founded Cellcolabs in 2021. Two years later, the Karolinska facility received production approval.<\/span><\/p>\n<p>Production costs have fallen rapidly since then, fuelling hopes of a tenfold reduction. As prices drop and output scales, Bernow has his eyes on a target: \u201cto truly democratise access to stem cells.\u201d<\/p>\n<figure class=\"post-image post-mediaBleed aligncenter\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-1414729 js-lazy\" alt=\"Mattias Bernow\" width=\"1500\" height=\"965\" src=\"https:\/\/cdn0.tnwcdn.com\/wp-content\/blogs.dir\/1\/files\/2025\/08\/Mattias-Bernow.jpg\"\/><figcaption>After spells as an ER physician, a consultant, and a startup founder, Mattias Bernow joined Cellcolabs in 2021. Credit: Cellcolabs<\/figcaption><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-1414729\" src=\"https:\/\/cdn0.tnwcdn.com\/wp-content\/blogs.dir\/1\/files\/2025\/08\/Mattias-Bernow.jpg\" alt=\"Mattias Bernow\" width=\"1500\" height=\"965\" srcset=\"\"\/><\/figure>\n<h2><span class=\"ez-toc-section\" id=\"A_new_world_of_treatments\"><\/span>A new world of treatments<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Back in the lab, CPO Lina S\u00f6rvik leads a tour of the facilities. Previously a senior figure in big pharma, she joined Cellcolabs after being captivated by the potential of MSCs.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cI was inspired by what they could do and by the idea of setting up a facility to produce them,\u201d she says.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">On a harvest day, her team\u2019s work begins at 7:00 AM. Scientists don full protective gear and spend the day working inside the Karolinska cleanrooms. Once they\u2019ve harvested the MSCs, the cells are tested for quality and frozen for future use.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The range of their applications is extensive. Middle-aged patients can gain relief from joint pain and injuries. Athletes can accelerate their recovery from injuries. The elderly could slow their ageing.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Brian Johnson, a tech entrepreneur and celebrity longevity advocate, has also <a rel=\"nofollow\" target=\"_blank\" href=\"https:\/\/blueprint.bryanjohnson.com\/blogs\/news\/i-injected-my-joints-with-300-million-stem-cells?srsltid=AfmBOorEW3oMUOPSQmmj0iOjFzWIH1WrhtAXdUS8OZSBiWSusE5-XcSz\" target=\"_blank\" rel=\"nofollow noopener\">explored their powers<\/a>. He had 300 million MSCs produced by Cellcolabs injected into his knees, shoulders, and hips.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Bernow lauds the variety of treatments. He says MSCs are interesting \u201cfor almost any indication.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">His path to them was winding. Raised in Malm\u00f6, southwestern Sweden, Bernow moved to the country\u2019s capital to study at the Stockholm School of Economics (SSE).<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cAt that time, everybody wanted to become bankers in London,\u201d he recalls. \u201cThat was not the future I saw for myself.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">He expanded his studies, earning a medical degree from Karolinska Institute and an MSc from SSE. After working as a clinical physician and management consultant, he co-founded Doctrin, a digital healthcare platform. Then Cellcolabs came calling: the leadership team needed a CEO and saw Bernow as a perfect fit.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cI knew it was going to be more blood, sweat, and tears,\u201d he says. \u201cBut the more I read, the more fascinated I became.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">What fascinated him the most was the potential of MSCs to treat chronic conditions \u2014\u00a0the leading cause of death in the world. \u201cThat is why I think we\u2019re truly at an inflection point in the history of medicine.\u201d\u00a0<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"The_new_antibiotics\"><\/span>The new antibiotics?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Bernow likes to share a quote from <a rel=\"nofollow\" target=\"_blank\" href=\"https:\/\/en.wikipedia.org\/wiki\/Joseph_B._Martin\" target=\"_blank\" rel=\"nofollow noopener\">Joseph Martin<\/a>, former Dean of Harvard Medical School: \u201cStem cell therapies have the potential to do for chronic diseases what antibiotics did for infectious diseases.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">It\u2019s a bold comparison. Before Alexander Fleming discovered penicillin in 1928, minor infections could be fatal. Healthy people died young or quickly aged.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A century later, antibiotics let us live longer, better lives. Infectious diseases are no longer the leading causes of death. They\u2019ve been supplanted by chronic conditions like heart disease, stroke, Alzheimer\u2019s, Parkinson\u2019s, and diabetes. We\u2019re also now living with more age-related illnesses, which severely reduce quality of life.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">MSCs, Bernow says, can help alleviate the growing burden of chronic illness. \u201cBut as a physician, what I find most interesting is the potential to prevent \u2014 or at least delay \u2014 the onset of disease.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">He recalls his time working in the ER, treating cardiac patients. A typical case was a middle-aged man who had just suffered his first cardiac event, now resigned to a lower quality and potentially shorter life. MSCs could have transformed that outcome.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Their regenerative and anti-inflammatory powers could support recovery \u2014 or even prevent the event altogether.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">To reach this potential, Cellcolabs is targeting a new launchpad for scale: bioreactors.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Scaling_for_the_future\"><\/span>Scaling for the future<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Inside the Karolinska cleanrooms, Cellcolabs currently grows MSCs on flat surfaces in cell medium. Bioreactors offer a promising upgrade.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">By vastly expanding cultivation surfaces and enabling automated, tightly controlled growth conditions, they could scale production far beyond what\u2019s feasible with today\u2019s\u00a0methods.<\/span><\/p>\n<figure class=\"post-image post-mediaBleed aligncenter\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-1414730 js-lazy\" alt=\"Scientists inside the Cellcolabs cleanroom\" width=\"1640\" height=\"1093\" src=\"https:\/\/cdn0.tnwcdn.com\/wp-content\/blogs.dir\/1\/files\/2025\/08\/labprofilepic-7.jpg\"\/><figcaption>Bioreactors could replace many of the manual methods currently used inside the cleanrooms. Credit: Cellcolabs<\/figcaption><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-1414730\" src=\"https:\/\/cdn0.tnwcdn.com\/wp-content\/blogs.dir\/1\/files\/2025\/08\/labprofilepic-7.jpg\" alt=\"Scientists inside the Cellcolabs cleanroom\" width=\"1640\" height=\"1093\" srcset=\"\"\/><\/figure>\n<p><span style=\"font-weight: 400;\">Cellcolabs is developing its bioreactor platform with the Royal Institute of <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/technology\/\" data-internallinksmanager029f6b8e52c=\"4\" title=\"Technology\" target=\"_blank\" rel=\"noopener\">Technology<\/a> in Stockholm. Bernow expects it to transform production, multiplying MSC output many times over.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Full-scale launch is slated for 2028. By then, Cellcolabs also hopes to have compelling new evidence for the benefits of MSCs.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The startup is currently involved in promising tests in the Bahamas and Abu Dhabi. Both locations have created progressive, patient-friendly, and ethically regulated frameworks for MSC trials, which have made them industry trailblazers.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Across their test sites, scientists are investigating treatments for a variety of conditions: musculoskeletal injuries, knee osteoarthritis, cardiovascular risk, arthritis, and age-related frailty.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In smaller territories such as these, it\u2019s easier to update medical regulations for emerging therapies. If they\u2019re successful, Bernow expects other nations to follow their lead and accelerate their support for MSCs. The potential benefits, he argues, are enormous.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">He envisions the tiny cells shifting healthcare systems from reactive to preventative, cutting costs while tackling chronic conditions. Our lives wouldn\u2019t just grow longer \u2014 they\u2019d be healthier and happier.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Bernow draws a contrast with recent advances in Western medicine. We live longer, but our later years are often marred by frailty, illness, and a confined existence.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cWe\u2019ve added years with lower life quality,\u201d he says. \u201cIf stem cells can delay chronic disease onset, we can start prolonging our healthy lifespan.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">That doesn\u2019t mean, he adds, that MSCs will create a fountain of youth. They won\u2019t expand our lives forever, but they dramatically improve the time we have.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cI want to spend the first 100 years being highly active and with my family \u2014 with my children, my grandchildren, and maybe even my great great grandchildren.\u201d<\/span><\/p>\n<\/p><\/div>\n<blockquote><p><strong><span style=\"color: #ff6600;\">If you liked the article, do not forget to share it with your friends. Follow us on\u00a0<span style=\"color: #ff0000;\"><a style=\"color: #ff0000;\" href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN63nwsw68G3Aw\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Google News<\/a><\/span>\u00a0too, click on the star and choose us from your favorites.<\/span><\/strong><\/p><\/blockquote>\n<blockquote>\n<p style=\"text-align: center;\"><strong>If you want to read more like this article, you can visit our <span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"https:\/\/buradabiliyorum.com\/en\/category\/technology\/\" target=\"_blank\" >Technology category.<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n<p><span style=\"color: black;\"><a style=\"color: #ff9900;\" href=\"https:\/\/thenextweb.com\/news\/cellcolabs-stem-cell-scale-inflection-point\" target=\"_blank\" >Source<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>It\u2019s harvest day at the Karolinska Institute in Stockholm. As sunshine bathes the leafy university campus, scientists inside the labs work under cool fluorescent light. Clad in green protective gear, they tend meticulously to test tubes within hermetically sealed cleanrooms. The containers hold the fruits of today\u2019s labour: mesenchymal stem cells (MSCs). Each cell is&#8230;<\/p>\n","protected":false},"author":1,"featured_media":683920,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/img-cdn.tnwcdn.com\/image\/tnw-blurple?filter_last=1&fit=1280%2C640&url=https%3A%2F%2Fcdn0.tnwcdn.com%2Fwp-content%2Fblogs.dir%2F1%2Ffiles%2F2025%2F08%2FUntitled-design-7.jpg&signature=151d20fd059798ee5c573830875581c4","fifu_image_alt":"","footnotes":""},"categories":[18],"tags":[],"class_list":["post-683919","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/683919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/comments?post=683919"}],"version-history":[{"count":0,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/683919\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media\/683920"}],"wp:attachment":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media?parent=683919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/categories?post=683919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/tags?post=683919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}